Literature DB >> 30508592

Remission from chronic opioid use-Studying environmental and socio-economic factors on recovery (RECOVER): Study design and participant characteristics.

Walter Ling1, Vijay R Nadipelli2, Naoko A Ronquest3, Victoria A Albright4, Arnie P Aldridge5, Susan M Learned6, Vishaal Mehra7, Christian Heidbreder8.   

Abstract

Few opioid use disorder (OUD) treatment studies measure meaningful life changes during long-term recovery, focusing instead on retention and abstinence. Here, we report on the design and participant characteristics of the RECOVER study, a study exploring life changes in persons with OUD for up to 24 months following participation in a Phase III trial evaluating buprenorphine extended-release monthly injection for subcutaneous use (known as RBP-6000 during development). This multisite, observational, cohort study tracks clinical, environmental, and socio-economic changes using self-administered assessments, urine drug screens (UDS), and public databases. Outcomes include demographics (e.g., patient characteristics, employment history, criminal history), lifetime and recent OUD drug use and treatment, and current health and resource use. Demographic and psychosocial characteristics are compared to a national, population-based study. RECOVER participants (N = 533) tend to be single, white, males aged 26 years or older. Mean age at first opioid use was 21.7 years; lifetime substance-related overdose was 24.2%. At first assessment, 334 (62.7%) participants reported past 7-day and 296 (55.5%) reported past 28-day opioid abstinence. Five hundred UDS were collected at the first assessment; buprenorphine (90.6%), marijuana (45.2%), and opiates (34.4%) were most commonly identified. Two hundred forty-nine (47.2%) participants reported full- or part-time employment. Participants were like a national sample with differences found for age, race/ethnicity, employment, education, and health-related quality of life. We hope that further research using this approach can provide data supporting the patient-centered development of OUD treatments and be adopted by substance use disorder studies to incorporate recovery-related, life-activity outcomes.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30508592     DOI: 10.1016/j.cct.2018.11.015

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  5 in total

Review 1.  Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System.

Authors:  Bertha K Madras; N Jia Ahmad; Jenny Wen; Joshua Sharfstein Sharfstein
Journal:  NAM Perspect       Date:  2020-04-27

Review 2.  Psychiatry and the Opioid Overdose Crisis.

Authors:  Bertha K Madras; Hilary Connery
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-04-10

3.  Projected Estimates of Opioid Mortality After Community-Level Interventions.

Authors:  Benjamin P Linas; Alexandra Savinkina; R W M A Madushani; Jianing Wang; Golnaz Eftekhari Yazdi; Avik Chatterjee; Alexander Y Walley; Jake R Morgan; Rachel L Epstein; Sabrina A Assoumou; Sean M Murphy; Bruce R Schackman; Stavroula A Chrysanthopoulou; Laura F White; Joshua A Barocas
Journal:  JAMA Netw Open       Date:  2021-02-01

4.  "I'm a Survivor": Perceptions of Chronic Disease and Survivorship Among Individuals in Long-Term Remission from Opioid Use Disorder.

Authors:  Jarratt D Pytell; Michael D Sklar; Joseph Carrese; Darius A Rastegar; Christine Gunn; Geetanjali Chander
Journal:  J Gen Intern Med       Date:  2021-05-23       Impact factor: 5.128

5.  Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study.

Authors:  Walter Ling; Vijay R Nadipelli; Arnie P Aldridge; Naoko A Ronquest; Caitlyn T Solem; Howard Chilcoat; Victoria Albright; Courtney Johnson; Susan M Learned; Vishaal Mehra; Christian Heidbreder
Journal:  J Addict Med       Date:  2020 Sep/Oct       Impact factor: 4.647

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.